Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a case-control study from Thailand

Cancer Letters

Volumn 331, Issue 1, 2013, Pages 46-51

  Ortiz Cuaran, Sandra ^a   Villar, Stephanie ^a   Gouas, Doriane ^a   Ferro, Gilles ^a   Plymoth, Amelie ^b   Khuhaprema, Thiravud ^c   Kalalak, Anant ^c   Sangrajrang, Suleeporn ^c   Friesen, Marlin D ^d   Groopman, John D ^d   Hainaut, Pierre ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL CANCER INSTITUTE   (Thailand)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

HBX; Hepatitis B virus; Hepatocellularcarcinoma; R249S

Indexed keywords

AFLATOXIN; DNA; HEPATITIS B VIRUS X PROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SCREENING; HBX GENE; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THAILAND; TP53 GENE;

ADULT; AFLATOXINS; AGED; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DNA; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POISONS; POLYMERASE CHAIN REACTION; RISK FACTORS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53;

HEPATITIS B VIRUS;

EID: 84873526153     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.11.012     Document Type: Article

References (28)

1. J. Ferlay, H. Shin, F. Bray, D. Forman, C. Mathers, D. Parkin. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. 2010. Lyon, France, International Agency for Research on Cancer. Ref Type: Data File. (Internet).
2. Wild C.P. Aflatoxin exposure in developing countries: the critical interface of agriculture and health. Food Nutr. Bull. 2007, 28:S372-S380.
3. Srivatanakul P., Sriplung H., Deerasamee S. Epidemiology of liver cancer: an overview. Asian Pac. J. Cancer Prev. 2004, 5:118-125.
4. Suwannakarn K., Tangkijvanich P., Thawornsuk N., Theamboonlers A., Tharmaphornpilas P., Yoocharoen P., Chongsrisawat V., Poovorawan Y. Molecular epidemiological study of hepatitis B virus in Thailand based on the analysis of pre-S and S genes. Hepatol. Res. 2008, 38:244-251.
5. Ehrlich K.C., Kobbeman K., Montalbano B.G., Cotty P.J. Aflatoxin-producing Aspergillus species from Thailand. Int. J. Food Microbiol. 2007, 114:153-159.
6. Bansal J., Pantazopoulos P., Tam J., Cavlovic P., Kwong K., Turcotte A.M., Lau B.P., Scott P.M. Surveys of rice sold in Canada for aflatoxins, ochratoxin A and fumonisins. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess. 2011, 28:767-774.
7. Ruangwises N., Ruangwises S. Aflatoxin M(1) contamination in raw milk within the central region of Thailand. Bull. Environ. Contam. Toxicol. 2010, 85:195-198.
8. Gouas D., Shi H., Hainaut P. The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett. 2009, 286:29-37.
9. Lleonart M.E., Kirk G.D., Villar S., Lesi O.A., Dasgupta A., Goedert J.J., Mendy M., Hollstein M.C., Montesano R., Groopman J.D., Hainaut P., Friesen M.D. Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry. Cancer Epidemiol. Biomarkers Prev. 2005, 14:2956-2962.
10. Gormally E., Caboux E., Vineis P., Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat. Res. 2007, 635:105-117.
11. Villar S., Le Roux-Goglin E., Gouas D.A., Plymoth A., Ferro G., Boniol M., Lereau M., Bah E., Hall A.J., Wild C.P., Mendy M., Norder H., van der S.M., Whittle H., Friesen M.D., Groopman J.D., Hainaut P. Seasonal Variation in TP53 R249S-mutated Serum DNA With Aflatoxin Exposure And Hepatitis B Virus Infection. Environ. Health Perspect. 2011.
12. De Mitri M.S., Cassini R., Bernardi M. Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections. Eur. J. Cancer. 2010, 46:2178-2186.
13. Benhenda S., Cougot D., Buendia M.A., Neuveut C. Hepatitis B virus X protein molecular functions and its role in virus life cycle and pathogenesis. Adv. Cancer Res. 2009, 103:75-109.
14. Kew M.C. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2011, 26(Suppl. 1):144-152.
15. Tu H., Bonura C., Giannini C., Mouly H., Soussan P., Kew M., Paterlini-Brechot P., Brechot C., Kremsdorf D. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res. 2001, 61:7803-7810.
16. Ma N.F., Lau S.H., Hu L., Xie D., Wu J., Yang J., Wang Y., Wu M.C., Fung J., Bai X., Tzang C.H., Fu L., Yang M., Su Y.A., Guan X.Y. COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis. Clin. Cancer Res. 2008, 14:5061-5068.
17. Gouas D.A., Villar S., Ortiz-Cuaran S., Legros P., Ferro G., Kirk G.D., Lesi O.A., Mendy M., Bah E., Friesen M.D., Groopman J., Chemin I., Hainaut P. TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia. Carcinogenesis 2012.
18. Villar S., Ortiz-Cuaran S., Bedi-Ardekani B., Gouas D., Nogueira da C.A., Plymoth A., Khuhaprema T., Kalalak A., Sangrajrang S., Friesen M.D., Groopman J.D., Hainaut P. Aflatoxin-Induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis. PLoS One 2012, 7:e37707.
19. Gouas D.A., Shi H., Hautefeuille A.H., Ortiz-Cuaran S.L., Legros P.C., Szymanska K.J., Galy O., Egevad L.A., Bedi-Ardekani B., Wiman K.G., Hantz O., Caron de F.C., Chemin I.A., Hainaut P.L. Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. Carcinogenesis 2010, 31:1475-1482.
20. Tamura K., Peterson D., Peterson N., Stecher G., Nei M., Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 2011.
21. Poovorawan Y., Chongsrisawat V., Tangkijvanich P. Problems and prevention of viral hepatitis in Thailand. J. Med. Assoc. Thai. 2001, 84(Suppl 1):S18-S25.
22. Ozturk M. P53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991, 338:1356-1359.
23. Jiang W., Wang X.W., Unger T., Forgues M., Kim J.W., Hussain S.P., Bowman E., Spillare E.A., Lipsky M.M., Meck J.M., Cavalli L.R., Haddad B.R., Harris C.C. Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line. Int. J. Cancer. 2010, 127:1011-1020.
24. Hussain S.P., Schwank J., Staib F., Wang X.W., Harris C.C. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007, 26:2166-2176.
25. Umoh N.J., Lesi O.A., Mendy M., Bah E., Akano A., Whittle H., Hainaut P., Kirk G.D. Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia. Liver Int. 2011, 31:215-221.
26. Chemin I., Zoulim F., Merle P., Arkhis A., Chevallier M., Kay A., Cova L., Chevallier P., Mandrand B., Trepo C. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J. Hepatol. 2001, 34:447-454.
27. Groopman J.D., Johnson D., Kensler T.W. Aflatoxin and hepatitis B virus biomarkers: a paradigm for complex environmental exposures and cancer risk. Cancer Biomark. 2005, 1:5-14.
28. Strosnider H., et al. Workgroup report: public health strategies for reducing aflatoxin exposure in developing countries. Environ. Health Perspect. 2006, 114:1898-1903.